Valneva Announces Appointment of Juan Carlos Jaramillo as Chief Medical Officer
06 Agosto 2020 - 7:00AM
Saint-Herblain (France), August 6, 2020 –
Valneva SE (“Valneva”), a specialty vaccine company focused on
prevention of diseases with major unmet needs, today announced the
appointment of Juan Carlos Jaramillo, MD as Chief Medical Officer
and member of the Management Board starting 1st October 2020. Juan
Carlos will succeed Wolfgang Bender, MD, PhD who will retire after
a hand-over period, at the end of October 2020.
Dr. Juan Carlos Jaramillo has a broad
international experience, strong expertise in Medical Affairs and
Clinical Development that includes vaccines, as well as Global
Market Access. Due to his diverse pharma exposure, he has an
in-depth business understanding and a strong track-record of
success across a wide range of settings, therapeutic areas and
geographies. He has worked in various pharmaceutical/biotech
organizations, including GlaxoSmithKline, Grünenthal and Daiichi
Sankyo. Juan Carlos was born in Colombia, raised and educated in
the US and holds a US citizenship.
Juan Carlos Jaramillo said, “I
am delighted to be joining Valneva at an extremely exciting time.
Valneva has a great and valuable portfolio of vaccines in
development including chikungunya, Lyme and SARS-COV-2. I’m looking
forward to be part of the Valneva team, working on these important
programs and joining the Management Board.”
Thomas Lingelbach, Chief Executive
Officer of Valneva, said, “We are thrilled that Juan
Carlos is joining Valneva. His expertise and multi-cultural
leadership skills will be a great addition to the company. We
sincerely thank Wolfgang for his outstanding leadership and his
great contributions to the Company and its strategic development
over the past four years. He has played a pivotal role in advancing
the Company´s lead vaccine R&D programs against Lyme disease
and Chikungunya and in building an excellent team. Everyone at
Valneva wishes him very well in his retirement.”
About Valneva SEValneva is a
specialty vaccine company focused on prevention against diseases
with major unmet needs. Valneva’s portfolio includes two commercial
vaccines for travelers: IXIARO®/JESPECT® indicated for the
prevention of Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has various vaccines in
development including unique vaccines against Lyme disease,
chikungunya and SARS-COV-2. Valneva has operations in Austria,
Sweden, the United Kingdom, France, Canada and the US with over 500
employees. For more information, visit the Company website at
www.valneva.com and follow Valneva on LinkedIn.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineDirector of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2020_08_06_VLA_CMO_announcement_PR_EN_Final